<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:18208529-7e82-4728-be6a-fd0bc0acc451,g:1f111954-4d05-432b-a89f-49b08039c9af,d:51a46167ef364951bf70ae9d6493776c--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:jnj="http://www.jnj.com/20230101" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jnj-20230101</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y180L2ZyYWc6ZDYzNDRlYTJkNzExNDU3Nzg3YzU1Y2MzY2E0YzI2Y2IvdGFibGU6Yjk3Y2Q3MTVmOWRjNDljOWE3YTQ2NjhlYWFiNWRjZmIvdGFibGVyYW5nZTpiOTdjZDcxNWY5ZGM0OWM5YTdhNDY2OGVhYWI1ZGNmYl8yLTEtMS0xLTg0NDQ0_17befa4f-030d-4ecb-b014-bbf7de1eb8f9">0000200406</ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y180L2ZyYWc6ZDYzNDRlYTJkNzExNDU3Nzg3YzU1Y2MzY2E0YzI2Y2IvdGFibGU6Yjk3Y2Q3MTVmOWRjNDljOWE3YTQ2NjhlYWFiNWRjZmIvdGFibGVyYW5nZTpiOTdjZDcxNWY5ZGM0OWM5YTdhNDY2OGVhYWI1ZGNmYl8zLTEtMS0xLTg0NDQ0_68d7cae4-aa1d-45b2-b405-6d97b9d102f6">2022</ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y180L2ZyYWc6ZDYzNDRlYTJkNzExNDU3Nzg3YzU1Y2MzY2E0YzI2Y2IvdGFibGU6Yjk3Y2Q3MTVmOWRjNDljOWE3YTQ2NjhlYWFiNWRjZmIvdGFibGVyYW5nZTpiOTdjZDcxNWY5ZGM0OWM5YTdhNDY2OGVhYWI1ZGNmYl80LTEtMS0xLTg0NDQ0_1d1b238f-90d9-4557-abde-158d499f82a2">FY</ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y180L2ZyYWc6ZDYzNDRlYTJkNzExNDU3Nzg3YzU1Y2MzY2E0YzI2Y2IvdGFibGU6Yjk3Y2Q3MTVmOWRjNDljOWE3YTQ2NjhlYWFiNWRjZmIvdGFibGVyYW5nZTpiOTdjZDcxNWY5ZGM0OWM5YTdhNDY2OGVhYWI1ZGNmYl81LTEtMS0xLTg0NDQ0_fc0e1e1a-a073-4c14-acda-c3e356741cec">false</ix:nonNumeric><ix:nonNumeric contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_97635a41-161e-48cc-9741-d517f85ec4b3">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_df08f0e2-160d-4a75-87a1-87cfb24da89c">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzMx_e32a30e6-d584-47b7-845d-23d4e433bc41">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzQ4_870a3311-5ffc-4b2b-8721-b5d7ead81c4b">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_21dc535a-a5b3-4717-bcb6-281e2bef1694">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_b32467a4-74d9-403d-8502-48e5120b86ad">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_baf92b4c-2473-4ad1-9202-3d7157cbead6">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_d20882e0-6ef3-4436-8245-6610c60bdc82">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jnj-20230101.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c37a522bee54a7797e1e6cb838f251b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24117e0479bb43b39fee8a31afe69358_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88ae5583fd7b47fd87a649c4e0bfef49_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1602ec71af1c48e8a8514b07a9371e2d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfdad04f19eb4b2788c13457aacbc7d5_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6f74ddd04b42a7beb1b698b449e828_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id42e890d27894b429fe640211353b83a_I20230210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i5b376816a5e84e09b89d79bed596a4a7_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe67d998d2674637a9c218fa218dce7d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic330177c89fd42f9a9a64f7236279ef9_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0d81a2faf2847ea921dc2fc7b6a23ce_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9807f0aec4641a1ac4bec134b355aad_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86826cf58c434c3ea3d165935690175b_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c5dd290ffc74ea1be26c69d111518e6_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2730b868c9a489d915184459e52ff91_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7e50ef6296740dda9036c6c59bae7a8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2bd92352194bcdb8a871945d2b04b6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie485eb6b64444292b2444b1661ce61de_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81bc749533a9432f82631e2ec08fb7c4_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i011816d4a7074b90ad92edd54a14570a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22968ecd8b144767bf02c951d4deb7ae_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i646e87c85036437b9c9703c88ff78a63_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica40f5d5420a42c4baf327e28f3ff166_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieade5efd55fc4e7f9b55b76ad9b270a0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec1f1ce9d602483b960c5f739d33f211_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icec2276dbd2e4d76878d45adc66f315e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef1d9f1b2874c9dadea9df7caa69641_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2339bc2da5948afb7331d7646e12408_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b341fec469b4745a481f3935cfdc814_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd8a9ce6ebc4c33ba835359ee340f7a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb64fb4e20f1404cbc6e31613ca7eef9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id693fb46504d40baa0ff184c359c60c3_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8ed0029b3204669a3f2d23dad442d8e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e876c735af9409796c44f0d4a41a05a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b74a9312aa14cef802c651c6aca0f51_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>jnj:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>jnj:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4f6dd96b61df4014b63f77ec38d4f931_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc105f8c066041479b85014a44b4f246_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if67355a8e31e4d4e89a2d4cc2404fd2a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a7641e1bba746ceacabd5c374aae1d9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bd05c5ccad24c3e9251efadcad9b101_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c19938fb98647cb9ab6821478e99ec4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe54a493eb1a41b6b7d5520bdcfdcbf9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f076cad0e094616a814262376cb5191_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4852527980040579d16cf952b6a58ff_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic46c5718fa2f417e8d7f7298244c427b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6908986b3f7946f8bf4a62d5cf5b646c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i220866b1cfb44cf7905eb75b0089e1a7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02fac9589cc2476b800ec305e2b17a61_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cdccdf73d6c4a2d8ad6277d9b89cbc6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd8fd68737c9443dac923965cbcebb07_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ba832f9031d440b8709fc80396eb47d_D20170102-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-02</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f986503ddc443e8b150a30eb4915336_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf53a7687af04964921188585c336575_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c32c30caff4e45bdfc303e877e94fe_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bca58ccfae247149a00663f0e2670b1_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67038bc29ba6469cb0cb5ca65068f855_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i632070131d164fd8a05baaff80e0d485_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icacfc2ccbd7d4914be4e26893f91b754_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib93e73399a1d41008b08bfb56335dc30_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00843ad11c494c3fb53ae75e01995264_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i519faf5a8e3a4305a459c43d43018179_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic073077c7dc4462981e17199faf38094_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82c0433d6c4941c9b80bb52a13ddf638_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a78016e63d142e2be872b5982def0bd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i257e8511898a47d39e8a99ec93263f31_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9c9e2118e3a44a88a2ba07a0b756864_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4c98dc571d344a8a06b677c3e8a1699_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if181e914ddc64a03888d0ef1285d38d7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ce066abcfe8429094c975b988b24365_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b15a0f49774cf698bedb20449bca68_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29a1acc3c1844b598aadafb03da80979_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if115c6f434d64fca899b4e6a5f072637_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifedc4ec86cd34c35b9afcab55baa12c2_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b40c1d088ec4a9789ae9b2483d16368_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id891cac7e84b467ea4fcc3186ec8542e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib504a49900c149668603de87c85be222_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibacac16e36314568b61aff5d3e80baea_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d8e5a2c62c4ce184e8d87099bffb41_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9e0ee8b5a704aaca8a9274822576332_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9408b29849f4c0b9380a8d9f61c6f3e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i282196aad12c47c99220e44da280b8d8_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i247541d8f154426a91d3065202f7ea83_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdfd1b47f49946eca78fbf8f06e72987_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i626b5e4c6aef4b478b14fa53c5ad89bf_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i406e87a2fe59450390cb44ac1a234e33_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d2228f7987c44149e5a689a665fe7f0_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e228c02951e4d53a756f82e5d074c5e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib43d5a9a7c574ba0a893b62c4b1938a6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie439be9218914ee6b4279a8133fe851b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib42b110678ca4863806a1d2bf6bd1bcc_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5629ac5f2c33469584439760fbeaa46e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f72a14eea6547cebb097d81ee48e0d6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6099acc42a42639c659499eeee550a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4784eb1517047d9af150653b71eabfe_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85328680ec914e0d9a276b4db4c66dcd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia324deef03f5433486883e8775658b95_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie72473fe7392450db0865cca43131db3_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe95ef042a2429798d99a69cf874da9_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1379957dc92040fdaa4530fe7c7b94a4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie385825a1c3f41b6b5d0e02f82243bb4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a29114e911461faec7fe4e8a9d1d04_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9ea9658839544de90b002aa4a145255_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc88406d872445a3ad6785a8573a5a24_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e54799bc7f7459f8e4524bc93b31c2b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab47b85ba2e7444aa7e1fb2845fe47bd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c2143b059d34074a2a1c452daf27abc_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2bd3f4828754f62ad5a5f11c2503d8f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife931fffad564c719966395e598010a2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab96c6a2a554d78b428a02174937f21_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e6a3d10477946979e7db7037955a625_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b66c56f1d944b9798daa8b8b05d751a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id306832042b14bc3bb6e213608544feb_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie74a64d7fcd74669819570ee01cfe012_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead1aa87d38f45fead8c4b6118f2e9cd_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e3bf19e86414044b7432eb058f5401e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i862297e326264912a68191b181c4f8ba_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i328303dfcaed4235be1c6fb645ddafa7_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i639b622f74424cdebe2c37fde791f0dd_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc528ec58784d3da8a3590dbabf6c70_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if363846d56154bcfaaaf3101bca3794f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28d922839a92453babec3a62e5dd77d0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73a1657c370b446a9a91aeb39ed80cb3_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b9d25facfe14e558d8538281e17e27f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eda7450d4d9456b9e83912cf600f6da_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98e6ade62ef44067805f023366e22a49_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d9971dcb124172ad9892da8f77ed8f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c15d323b29d4f51a3b0277a6efe9fcb_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i260cec3db7e141a7bab9fbc38d51513a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af51b0799c94e2f99fb3ffe042cf726_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82dcae20ab7f46d58205e38411c02bc4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic45912abb9de446ab846fa3d96ef734b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56073f5e045041e085b3b01d323734e9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6e64db864e94433959e07e907b7df1d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55999a6bc9a460e938066f5c6f50247_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b7dae6e9bb14eb495b8a03281389def_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44cb3ddc5bc04bb699e468e1eb79f066_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e4545ac2dc1439cbf7c13f15c6f32af_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc946cef90d46caaddb4f18c8fd5893_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa09240ffe5c45a493822e57c2dc3858_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb9f80f9c820492780c7f8c91535919c_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14cee3a2fdc941089f344ca72308f0f0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a01ed372cd4e95abefcdf0e51356aa_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8143a538b2e94972a97a82b7e6ec6c68_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b5eb91944ab42f6bd12eae5c9d5ae5d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb690af5f3694f69b7b889d872aeaf05_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic136e45ed1b94c44a821b42b608d5c9d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7980b23189f4bc7b2e93c0103862863_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef91f5dac5a431b8628840f5ad90267_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55d14fcbb70445388964f5f5d173a93_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237858b83a9d4cf297ac85f26bb8ae97_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab7309c98649499d9713793656af22d7_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f081c66b1b450a84f5571770ed1022_D20221003-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f4dde8b4404aef8dca3c97bf241db1_D20211004-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e7e250084ad46a6a9cbab407dbeb7ab_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c81dca775704665a78c37783de6d091_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8d53c59ceef44b389961dad508f831b_D20221003-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ae9179932924168b60062ab11671493_D20211004-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6534a66bb873492c8df03d6fc07250d9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i828e3ede8e3549dc9f5058a9b4b0483e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb50a86cda447408f1cd7369b0d9418_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3e4435e5d9a4e60aa7205751e72f33b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f2f9ac2b4014e1fbb1ff7315cbbb47a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db883efd7e1433a90d82a1129bb778b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3133d52c339b4153b25eed2e42d701a3_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a9dbd90e4e4b16b09008c309918698_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9771bb6b36dc4c2eb9a95f16e382664c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5daa381fed7742f0a17f958e3f55f3d0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7375a9453abe472696f28e9901817945_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2864e7cf41c41f3a7a0337f807e5568_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bc84e4de9ae423e8fd3d6a2ad33e500_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14578454fa464922b37380e635487d56_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0310802ba8b84af0ab17442fe8266124_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia39659278be5497eb0de37bcacef7e1c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3d82bd1550d4cf091ae15cb452ce838_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c9291dfb5a14a27898df7a62b8d588a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29258a2318d3469e9984174d5a29a387_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie48b117336c44afdb375a11b9255f3b1_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ef2c7f6b53641888829b0aa74f1baba_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c2690afca047d8a831e4a7983bda38_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff70c34dd9b948dca087b12faaa08430_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d00501bab6464fa7c7be34c6d914c9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7cd5b6c455d48de8f7bf42de3895a90_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fa9b7b2390c4ef88b1b4a20e07ca293_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i853d7b4b73e148b18f6b3d77f487972d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4535c102f78246f28d354501ec8be219_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9da5b69b8f28444dbde29713e7b26de9_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i141ff0a4da5940ae95c9e2df4dd982b2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c7604b66f44fbc8b00fe1f4ef4b6eb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia68fbb4c6ced466380b79a6a0e444ecc_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3935ca62623944f3a9d651e98ee70890_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd838f2728344154a7eaa225122dffc9_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ib4be09c6f2a742c2872a7b5200cf5855_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1be16c858d742f980612d02fd786f2f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4adc99f2fb284c778be3f71c61bc0de9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ed0d053a547493695781065ce302590_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c69578754b841ad8feb98ac1c3242b2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b6971f2c45b4b4bbe271ae191423bff_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie38e52b1bfe842649d2000136af597c5_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5182d9f822204a00a480cc34f4ec92a0_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fe3adfe765241a28bf93429cd742b69_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34b79ae775034104a023060dd2d5ec9f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie437d7bfb45f4c6995ab0a136f5c1320_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5971a213eabf4160b6e3f25559619b06_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i12619cfbbd3b4411975c686625cd4ee8_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id160170994a44083bc75890cadbe9623_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4b486d1b1024bb589a658274877269a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9afa533d623446aaad16fd946291ca1_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5bb2d0484d64d079887869bc2c1d3d7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia73e0d2b294240f09389800e85e374d4_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09ef46ccfc64f829b503e8d23112272_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e41ec0707864b1b9019a8e24ae75a97_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168bd65ad6a0451d816d411b7f64f62d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeb93d53afa248caa20093bc023648b7_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22bff2ba3f0e400a90a0044c29f13928_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia496b34d6cb74a168adcb5bf7122133e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92f030712061450fa2980a5ce6c8142a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7258a1e04b8c4f889adafc8d5386fd96_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602d89dbe75f4f748c2295cd5de57aec_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i423501f49ac54505aa65ac29a7fd6d80_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d49418e0d74c1189e8912cc7d7675f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0326f0db384917ad2a786fa145a98a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf8bfdbb53ca42e3af2e559cf8fb62c2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie15d3b834f6345ec822ccb7085d7c0ff_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8db5ee980d1342e793d3791eedfbef40_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65b796c75e3b43b6bda7c9efb4daa55f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad65bba4399943f9b1454685a4155820_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd231a0bb104e1684521862f1414b9f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfedf7be284043c98fd18f790c2086ec_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6fe30488d441739d3babad588015ad_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a23940668d946ea8954481965daba62_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ba6c50490e34f12bda5adb99407a82b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd4cdb4f57b84232a93db6b02e61c82d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if509cd02d4494abc9bae248548e9fe2b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8dfee6b2b9f486783bc9cb6cab9a4dd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26b8da89821f4ac284bd3d5d3cabf51e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cf6df4972c749909f6092392e43369e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i696b5a358a7a4568935c7e93c24e7f41_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd634615b6a848fa8f9569f674e894e6_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7967ec234e94809b83f6d22fbf9ce9d_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia97fbaf7b43e485e95cf7e8916d74a96_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if61dc0cc1b304eaa99917f19dad110d2_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83fdb88fdea44eacb07ca88b7b8ca7dd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9293aa9d30342248d3d85c512c81764_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i565be597706647e888d0c0ea676ef094_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26f202863bc94082a97d142a46e8d1b2_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if67ac9c2c837491fa49ff3662e87bfe1_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib10ffb3abaf54da0b43cea2e2ceb7e08_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1902162eea4549f78cee91e0c0156868_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91feec6def3047ae92ab21665e29fbe4_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefcd48741e0b49cebaf892a4bad31d22_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f24fb8b890841428b85dac4bce5953f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86d445ff094d4648b596d34b86e80355_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fad250982dc47abbb5a254928d9895f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e53361c290b43718ffeb7cd8f9afc2d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46a29376f79d4b30a03d32aff4ccdfe8_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id01a95b64b3942d1a96051a89d5e3413_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f90c4157e04d8cb1fd3fca5f4ecb65_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbebb1875a3d44ca9658f3fde18446f9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac989accfda349e1b99a6c9cdcdcaa17_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f53b7ce48b043d2944b5ea32ee20998_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i608e0e39b1eb42ac87ce9ad42b7316e9_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d8b8a1c1b90452cb498943d7fbd6cdd_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2821f9be6044964b18bd8dd41179df6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93cff80013cb4ca0867d9c8d85521e22_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic658f5e90fb74521b314a6664d0b97c5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5117957d990a4c01bf764aa9f770ef81_D20211004-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb809688a744a4ea19a1ad0f2b4bf9c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf8a0dc444a439691c1ba9c0fc72e52_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9abf5a6f4dd843c6bdff0c9b78680b08_D20211004-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic88fac17377d4247a40066aad9de7fc4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id39169ea988c4eadb476790566c83233_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic89e3ab0d07149d68abf9f2332bddb1e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40d1a3a2e954c59984259c6a56987f8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6823d2e54e284392b4c4cc465f125c28_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38c867d387040219eb10b7ae2cf8194_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i381b1781da63498caf01563beb9220f8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i160fee01a45e4e15969651172a1b8a52_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i703d5232b81a4b55936dd90e0dad0606_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c7ef14eeaff45dba385c284096876e5_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee7e142ff6024167983180ffabb98005_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb66bf1fb1c43f6b51ba191f9fdbc89_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i568e2ee4449d4f8280ec25b22561b13b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf25c935e9904a50a945cc29fc06d712_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1330068050ee43c89fd0edf712d3cd33_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89994b04ef5a4989828cbb2641ea63d2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02d251447a4644728a4ec4ab07eeee7e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbef14fca11e481c8e30ad28994f26d9_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee98d3d2af347e6aa674a643b6056df_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f2b519c9234298b0417a7077818079_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c2557ba884340dcb35175f91b95b324_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9ef98128abe4aedb0a5007195b08de1_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a0708b59e24d4ea0866aa54072a7da_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c0a56ded60c4a9bb35be25cde1c1637_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6a1005463744b0db3476c6fa293b2a7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b5854265567407d8c334a909d643d48_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e0ddcdbf4c44c2a8e38032719cfecb_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i065c9f2a0f964ee285c2b8a25d0a06ec_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b6a8806889b4e03a0a58daf7c2e8756_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dd0d8c6503a45b587ecfb92769cc43c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74650ae05ec94371b9d6bc18a602bdba_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id57112356ae147f6acddb2fa2ef3c2c2_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b00037a81c40799e88359b6a3d230a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4e0173b76424c5f8b69bc8e9ad909f3_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11c5835ef6d041e0a21935aa096c3e34_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89fe4d1a68ff41478d904f10e0e0ae0e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6e4971765ee45178f66de2094bb223b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2558baea70f43d6a6cf9affe1cb228c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaa2fb24fe7f4913b81bd9b6e6a69211_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia65b35d656b7404cad2cded1a7f84257_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13253a658c83423ba8e9c1af10e40f9f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfffbb437b674ebbad4375b66a624388_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia30472b13c2c42c698c7f0512ec7426c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f96d2d3087247fea72a69f7464a8ffe_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic562463a901d4f7d98741278df63a71e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i040ae04cd8d34049b557c7754b4d1903_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a4136d235304b9ca96dc52ca2bae31f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aca2e86db254efcb60046d3b1959e83_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i629d668c721f43fa9a69ae248da4c767_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27927d8dc21840e0886a91b302a75133_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72431f66c0344014974314a2d6fcebee_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6053a0abc1f746509f25b60b89e316da_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1c3b856e495487fb9397d837ce7430d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a93ad27dcc346cb8ed7ba5d19476117_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34cf66c98020432c86dbfab2c8bc0591_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i907758fcc942478385fb4e997c7b28e4_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if460c561b88c46f197e086c2eb780175_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if667a81b90034bb89345e0e86dc1c837_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie873bd0c000344438fb4154226263234_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14706b8e4e9b45fa8ad2b00f7b025b13_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08e5d2a42732496faba5e2998478e99f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c63ed9d635548eda5b40167be502d34_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c17edc19d844447920bcf55fcb965c9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9464afb4525c4171b9f7c85f564ca383_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678ae776bb3e4394807bdb4118962522_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbdd72723de74d5ab22897210e1d235d_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id16f7d3ae47a40419613a4e6ebcdf931_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94f0cc6d1b0143a7ad0de6a6b7171527_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1489b8c66a064c22a4d320bbc28a949e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5684bd25916640ce8a21cd76052a6a5c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5175417cdaa471eb56e2f0adbf22f49_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4522e617517843a2883f058c7048bf98_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f898d8c94c649a4bcd40d0903b33a8b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d78a014cb7b4600b9b987e0c8d3ef4e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9eedf365257482e9a59a6c5f27d0a37_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i409919d7e88f41b790a753d01b52083e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db77b85a6024162854cd564cb20a41d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e09026399524065bc97affeb43c546d_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199aa9d6185f445c8a0e845551e8cd3b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44bda01bf133404387afaead8b97a718_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccce90dd21004e5daf45ef5005ed0551_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd19fe4f42064eab8bbfb528aac6c080_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74f4b70efeba4325a8712247faf7b3ff_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc3e95d2480f4b09a43e8526cb530ec0_D20230103-20230103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aaa8d30ebdd4b799164c6d64da029ec_I20220914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:December172018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie95b18f0bb224ce39159e2cece26a7de_D20220914-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i998292a4720542fb97323e8a21027018_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d2f866128a4c0bbd34f29e255e2e5e_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2e5b348e871404cb444f06edd6e8a44_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72f9f2cb97f549a783317a29d6bcb3a6_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bdd796b17934806b83c05e06ce34090_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdc62ce8bcb249e58d2e978447347cbf_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd018d59093549458cb4f3761ccbb821_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b330b391c664593bf5ce01ca6a9e387_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1263a8933f94cd2b1db256f5159e8c1_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86541415a18745ad9fad6d5a9da21dab_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56cfe48a1389431abade9bcff2c63177_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a4b14144c8b45d7b5c9ed3c00162124_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic08350f7471944cfb12cf9ffa56a221c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i503c1b32967d4343a8eb327c8c6be661_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i602c299adc484e92a89fdcbd8f6fc8cc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief3f111fd6524bf78a21c828a283c3d5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0b83f8ef9bf4d359fa8bb52b6dc3fcf_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaba6b6f0ecea42ebb8ac410bf2612423_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1d1b96425db42a181eb410f603a9c9c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43fcad8870384544ab9df6081f406c7f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71c7679daebf4d0db0b277193d8ac50e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d61a4fb2f4474181a28e27ff866f5d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd635367c6c4ca58981a78d2275f2cb_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d00a4d2722e40608c24963350b6de0a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf4d10f59ddd4ab8bd56434bad43ae20_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5800e1082b6146cea9073bcfbb7f02fd_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e067c6346f74a20b1c0fe95515d8e9c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4ddbcdadcf848e69b32b80c8a7d34f4_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="stockbasedcompensationplans"><xbrli:measure>jnj:StockBasedCompensationPlans</xbrli:measure></xbrli:unit><xbrli:context id="i4a0e319fb645457cbe71977be1f29fdb_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:A2022LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33dbc6eb904844ee90275f3f8b7ed3ab_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef74a38473e44019ba37eeec97c7385_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847f3b4e40ed4892b6cd1c9603a89184_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14d568c675ed410f94bed5ff0929c46a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a71324ab9d241068eb20d3f9cd41ba3_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad9b5fbc5ef141b588c3ee79455a9741_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07803580a3e146b98a24a385beff349a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34afa7b8b8a04ccb830c793de735eb10_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b1e92a43acd42e993eb03a79e248489_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i215808acd76647669f725a762f3598d8_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i354df684ca7745c6aa4c8a3b46276a9b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c10dbb3a1594a2d8da6daba7890426e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5256f81d8e4f98b3cca09bfe121aef_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife13ff98e4674d7694f59286307e1d2d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bc3aa29768f417584ae7a6a6eda8f3f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2cad4d651314028b720522ec64631ba_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb399cca07bf4bf1a81d45b257cf9c08_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71da035cf1914f3b9868aecc174233de_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc0d59a1f134f84a89b363a070d1183_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec99756e458a459cb8bef3fdab17c001_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab9745c050214279b0fa340682e40433_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69db6ec00d174b129e0e5cb215633ec0_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf40cc2fafb74f6c9d2be93eeff661c6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec1fd52e3482447ea1b11486ef26a9be_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2198f462491444aca0da61923b632a27_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ce09bf2900145f1a937004d1c00046f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f84b91d4aae4af0a05f5090f62c6609_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58914e95bbb84bc5a9ea2cb7385bd869_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8a784927c1c4189af0712f9727df3f0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4e29289044343a48f06844e7131ac18_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3ee2aa1541c4993ab5a6731b5086c7d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2433209091f4b3d9ccc6502e13af23d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5735f3b990b141e4a4be776a1cc02da1_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62fff57daefb4ad48862e19671a6dc9a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i439805017432405eb34a20668de55a4a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcef65e498e74c66bbc548320bf01eda_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56cc8799267a4d1bb446fc871370346d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id06a8fbb2c854362baef8d48b3e539ec_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i305f2baf4f5040bfa89c742f613cb693_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bcd6c0066854e439a15990c5325aea0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife8ad7f9de9f40939e7def44ca83e3cb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i575246cb13cb4e958a9cd5c6a9682cc2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia568e79890ed43dca885e271433dca1d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6438bc69468141788dc7dd15c2e6f0b1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i740d75bd86104d0c94afefc9b87d51ef_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aff1a3d834643a8840f76c325a3a99f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b07581a92b746fc9cdb03ab06449ec2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6514fba7e78484d8e9d6a382b648d8f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieef3ea0559af465c8780f85fc9c95f1d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i187c9f9d5d5349338afe50224cc27c1e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf17bd3c525a4b3bb0011ec89a64ff51_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i193f625c1b214c7793df54d141c36d73_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i042187f7809d42bc81ee957ee586ef6b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5671c06ac22418998bf233fa3ac24ff_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1f0e48a118f4e0f8d62b1d1fbf833aa_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cebe4ddd2e04f1cb5a741a9533d0a67_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fb8ac4e52c9497b82e8cd22bd29d272_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015e212fa198442b8d18e922914d6075_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81bd67b3b0634ce4b563b42531da6b02_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i001c88dc32694c0aa767413204814f97_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb68778688b84eec8b98dc05b1c73823_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ee93092fc834bb3890c0d900445063e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aa6061cdfda45b48d4a19e23fa32015_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c2531fa73d44239a380b2362f5e121d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8578159027f24dcf86568156693183a5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id93ba1dabe3f4b5da204b1077b4518d0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bfbe7c9fccc4c64b09c41d52ad70175_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i263452e9213e47c886650ce7cb371065_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d7ed3b7665e416388b6a9aa612a4869_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4896b102e9542ca93ed851ae014915e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1269622a495a4e64ad8c2c22a7e91280_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fb3b41722c44fb497e08d86ff98bf18_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1082a9661ae476683c756bbaca58883_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if02a3937e37448db80bbb8a99ffff4dc_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2292a22d2f6a4e18acba13c92c14b1c3_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib87733bbde604e8f9bd05fb51223e407_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a442a0814740f1a1e5b57d6e051977_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3285a500e83d4e938ed7a18bb07f562d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3c3b87812e3421384238aff93cefacf_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc2c65b893a44bd3a5dff496a5a117bc_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1ee80a6d40c46f0b266441ca6963f33_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43d7081e6eac4175b0632049d45aea0b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2956c17ea2404b80a4eb00815a6af4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88289ceda63741c295f461bebbc818d7_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie47ee78762394fc48eeb03bbee8192b3_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id69b428176aa4a3cbe479f87f86f7bbd_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieabc073d9ebf4111b8a8d92bdd0b8b7d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e88cbad6cbe49bd8e825a7ed41c9c3a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e22bab2b8ce4579a43a60a12cd1a9c5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec93cf328ce84ef3a066a9fa498ab413_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i986b4a68a2bf4fb0ab3a4d6b014ad0b4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if74c6a56a65d42e393222e70b8ee3b45_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7849117524e141089fc6dba149013836_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i397c0bcfffa744e1afc241f015ce8b04_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if478f7362b5f45038c0ff48e4dd32d76_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i002e689e81af4469875bf4167de1a9f3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12bc3574823a42a18c54341c7e48ccfd_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72281ed8b429494f9436d47de34888bf_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39cd91fc937e48888264b49955721321_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i912cb26a60ad460497cb59430e03bcd6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4af108e7bc8424987da6ec7762b48a7_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe204b8f9621439b9d7201393c46acc4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9e7de8698c4e4b8582e62338b3a308_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1893a467cc624e79a62e62fec246d121_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50aef40f53704f639eeb4ead4f673ed0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i150c9d621d58436592cfc84eadbbd8de_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd61c709b4f4822b6b0abb800e70ce2_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07927d37d35247c4ab9e64a048a34675_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idce1aa757100453fbf226e404cf449c5_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad404b1e843448c5a861fc281c54f700_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d6f86395074f92b284bee5e41b9c56_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59a2dae302645e09d149c7d7a174a78_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafa5cf4ed7ac4030baf40b5dbd7736bf_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i692eee4c082846c498f4462756e57681_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3834f86e6904624bfc14ea56990f87f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203194712a9c4ff294ad81780e8d8a52_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc9b8fea3634731bf270a2f122b7d2d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia865193fbf2a4050bbe5db56a5edfd29_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab664701a68493eb072fd6ca439c0a5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16dc654ea1db4b339475642249680907_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80dcf3087ead4df5aeb6e738124670d9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d161ddece944bf8ad540a6a199f574_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6fdb567ab044e4fa2b02db9f1115bc1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf99c2470714a549d4827198b5e4306_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42f4fa8e366c4d2b8cfaed938a637eae_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61655eb3ec9a40bf900bfa9966b2388f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ed4bc48a164740854aa44ff42c7c43_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d721f0119c44c98b11f757b023c30a6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic03f559a7b2b4eb3ad1bd1999053ca64_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i476d6bdc170f480880b6f349fe1d02a4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i655fec7a57304dc5b69e3c08e261ce49_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6870ec4af934c098b1c08e0fcc5d5ea_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ebfb3cbb91849ffa928740c09fb6845_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7187388ca7ef477bb2a513ddc7d152a5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib767315f9702455d885f117ae21d3c8b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf85e7c05384372a344804b1789a29f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacae22ebe7674dd6b631866883fc36a3_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide93fb67d26b41bcba491ed0c9028795_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5952a4c02d1407ab7d93feadb356126_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d48aee7697b440ebfe16cb49fadabe5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ae8a2a744646ef8a4dd8027eff0ee1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf92bdfac4a45ff8d99efa6eaed94c6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a36def101eb47b484d4ee34dde2f395_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111650d10ac748e7a9e029ffdde290cd_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735de00a843942b69ff5f4e4395b0611_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i494446ad1b9140cebb18afa776b08b68_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib33427d3662a40198bb45dcf433c1468_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if823818df08f47e38c8e54ee1da81441_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9098882055048acb56f0a7daff7b6cc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9abfdce0d16e405883d49726c32f1acb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddcc1f0bfd31441da630d17bcd07bdd5_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2117a45f239d496da7c89c744b4799cf_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic396314e70cc4e8aa30c901f000516c6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice5729f779d5409483631d4dc721f7d2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7789339e6baa4ad0abaa2c19f511a483_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92e52543ccad4142906214832c2a1522_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i133db46d59e84bdab73a70f71326e38f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2853f108a89e46679d84a145dc7f721b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i739fdbf5c9b249b5bb242066485fd13b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e252aba7cdd4ec2a540688ab64830b1_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d36aaa849d34410912a18791f8c1fdc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65e91319a96348ee87ae160ca65edaff_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i681b21f0446d4385936cb77eb4b9dca1_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib410879725f24ae8ba0999c6d06366a5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeb843593c464cb18a4c3dacc904ae00_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35f94389fa524ab289f01a52a921cf7c_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe39ec345a94ec18338abc237e01452_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie433d85e7b6448d19d8075af0de26e2d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc2c48e4eca4c58b9de0abae4adff22_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib44093e5c3a0432f8560133ae4395d30_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf0b6c7689e44b268e1b721f04f9848b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b87d067ef004f5aafaed64f58162f4d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41fb3351d90d4979bd4aade9045ceba1_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19991ad08c1340cb8a9f12dfc8fbf112_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i186ad1cd9a1e4945a51acd1fbe039a6c_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2534504edb8d464f8ee62a5593a78d54_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20f893fb187e464aa1a397a82dad33e8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffa2c64baab1439f89e0e380d54cb895_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b8737e36dc40e891fd7257c424ab9b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if08b714b754d43ffa7a441ceafdc12db_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafa49f8cb28444c08b3e7691d9289fd0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b32cf9f39464d33a7bac9a57081607b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce1d8aac6f64a9e8d3edf11466fbeb0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a6257c648ce4c319ca04351b1ac19ca_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd0f4a707d5c4611ba64f2bd6e1a1cbb_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae286eb23a9649dab05aa0c949e37a1e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8e4c1f3ded4e2683fd1b1d3d7f2f3c_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a46b60d378740ab9a53a2c913e6fa9b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6008938b9b8142ec828a603dc31c9ad2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd9ba3232ba45e7b1a6b4629a8020a2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531f3041cd70490aa0a614493a0966a5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c2c03afbcdc4c75bc0ae9b17f75089b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402fca2f518340d8af0930c93c070ab6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e268daebe694083b67a5bd25ccebbaf_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ed046d3cd9f404a967c40585336ae5e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d6c31d76c79411d9f1e91f496118539_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89359ce197324e7d8e9b12c16f4d715a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38900d6ebb345d29c6d1b684d8bc793_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief7ad9c3131d41be987d8486d4ad049b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc6f1927b774f8d96f04fe0a712fb86_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if22f8c6bf53748f190098078cc426ff1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6610d754863471e9d5a6fed947d250a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i388399bd3edd4e449f4d93d8915eb54c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia806a9dc2927417fa00d06260663112c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4a41b434b5643ac9706b30fd05f05cc_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c01b12144ba4292808074086604f6b9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfaa8480658d47aeb19114550474ae8e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e93fc3771554eaea942a7d80a2a5191_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5235c523a314775ab067969dfd06501_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d7ae90ffe640d1b0883b71099f3c5c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c54db2a9f24834a5cd8e9430746ef9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1925b3bd72f49578ec926bb8b286ea4_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifec5634cbb6c4bc397afe138e65efc43_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26dc3482b6c144828d2d9c88adc29ae9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia24bd46b2fd04893b597d1d6c0898eb7_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7228601370344a3b7c098e83bbcb756_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc6bf38d4874b188bd7a4fbd673a97a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6698df7c52e241f69da5dfaf96df667e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8692c4c3b564eeaabf2e1b6e509764f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb475dbd9dd64c05bd7d3314c41d69fe_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe678f07567c458196735fc6dbe00d17_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i605fa23baf2f4ea78746871328fb7ead_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae81ec5366b14326a0b7f0c13fb74817_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9404055d94a45daba90f61bf0fb4da5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f2a17cebf7348ba8a85d601ef95950d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b4e7b35d9e54a27b148b95717e09f65_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46565c94f13f45f4b15ef2dfc93ac248_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269786122e034c9a8fd09281eddd8ce6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie53f9949f4d84aa5a52762670bfefd4b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i324b80e3c3ce440d9637c080549788f0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e21a76b60c423bb70648b1c526109e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531753cbd8df46a191a33e3a9070c38f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26f47936bebf4e8e931a42d37ff16544_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff8d6fee31d84079a124b85f43dd7a5d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i258d249f5434470bb702dca877dce7cc_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bf95a45f3b7410cb1201a2856109d72_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i262b23b4cfa3413ea822c90957dc8c6b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b8ea85287e48b5ab16ce511107e30d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d14d3af658b449da07dc0be4f9a9b0d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7520de6a9d0449ffb1547564cab682ed_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68e64b453d6c408381dbb9d6a4335a90_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c85d4146adf40d590c1b983de215889_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab4f46984eb74afe9365b8352076078e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42467f46f4f94427ab2e63069eef5ae8_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ffac75e48304352a8dfea6d5c6ab3f6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i646423bb9a524219bf440e4800663ed3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if600a19a06ac46f1afe1fb53208669c2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddfa392c8b99451a919767258d532fe5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic353f059b15e42808dfe31fbfa26b20b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d81c1fa8cd49908a0537e36e44cae0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0bfc95e5f50496095f0e7adbac02fae_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i081324fa191f4ecfb64d5fd21e4897f8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5a747f1894746c18acebe55fcee36be_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9952f78ff604ce98857b34e7d2d4ee4_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56304f6c91134b9ea995c8c26f92fcf8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1170f44e3e784c13a897d1f33b657d36_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aab7e608c8647bfae8078c104427a5e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98cb0d95137a4c3e932962b28dfea7fd_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7df5c5bd36f4c42bc5a42a86e4787fd_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib995e35deab1419bb10080c3e8bbe15f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008fe96bbc464d418ec59e61164bd16f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e40224a7adc43c8a51c165cb1091d51_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e1bf9204c548b1a2ba79c5c9f86b69_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d65c31f1e1e4231a4590f52e12e147f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8696093b3c14612a5e87f253f041390_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i013ed648148d4e64a510c4039f176525_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ee4b03f8ff435d8d7e8b5936462ff2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1bef826f6694533ac45bf2390d238f4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1ab414424746e7be5d469d0581e83d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98d58d05f93b4a88bda30ee75b9bd330_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf89a91e03874addb0a5a3f057b8bf3b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic89356ecf07b40f0a9a2da3ade617700_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea1ec1749cd4cabbe3791c077d397a5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee811815defd442b9a2cc33fcd46a0d9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie657f643b4d84751a89bb88a4ad2046b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fc87b939f80405381cdf5826af23b5e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b389620244e4707b32be2326487bc32_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefecdd362bfa4d2db19e395e947a0d65_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id84af39344ca4fa5a66b03352afc5e18_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b76b01e302941c287997d97c3f61777_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6936c2410a964df4898165a8dde602da_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7bd843dd374433190aa473e3d8f6192_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76995ebc9d3b42ce851ae92a54711982_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36a27cd0e7ed41e68d19c477b421f3c0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7001035b825b4a55830f9093152ea514_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba577ca1802747c39cfd14db4de2c73e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a17dd172ff4c2481abf0f956446b82_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1cfe8125bf4f15bb0a5e1a59589712_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe446820d2747f094272bcdc9f800bf_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8757a22a8743e3ac6b47bb33abf088_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6d1cb780cac40c392f1b55b06665d46_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a13564b2ced4d028a7c3601115a89a0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e26b9b503db42389ed14ff2087d196d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i374baaf3b488452d89425765aac44db0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a7e09f6f90410eb6663244cbe7e73d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cfc4b069b214a88b076bd5e9211de36_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf16b29572b6423cbbce71268561dc2f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5463962cffff4346b6f757fb352376bf_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4508e19a81e14913a4c1c511d2086478_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0255ba511594a8bbe1f7b35cf65502f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22de2e9856b44e04a06ccf411d64efe4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dc14570d9244e2aa7a97f84bbea32ad_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icce2f7bceb104ba68129e1d88ba12479_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6137d6c2ae845578e96f2f9558e743f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b1ade7237d24dd7ab77638d8c40a4e7_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95b5c4f0629a4cc4aecab891a4bc05f0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb55d931932c4dbfabf0ea3d29fbb324_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5becc7177bbb4f019eb9d2832933f156_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic28b731dc2294261b6dbf518da9544b6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b6cf0ef3640429391dcd90960832aa6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a56ab7b9ca24f89852d9e93dffafe9f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8e2a5ed832e47a9b4b8c86beaaf4733_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb95d7922c64ca28dea90d41bac3081_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if85629f30c724cee9d887e6dd896ce8d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b8655d882ea44638ed3ff1d03bd0dbe_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30916c73190f498bb12adcd4eee7e812_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b7c39109744471db0921f5a010a74fd_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf850e2559a44ccb6fb87628e4893d5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c76de98f2c417a87e983700d3295da_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5500ee09e8148309c05055c79c1eab2_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccddf880ad6748c5b0f867362c1aac4d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i799adb7b649a470ab60c3ff073dc1386_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9059956b7ebd4ef9aa0ca0715ffea91e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36786c954f1b44aabdb08b417155a2f2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8f249bd22be4ccc99f79b41ee68c3cb_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaea127e21314435ea7a422bda430700d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f7eca78939441fa15ec6298a45d1ef_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32cf8ca571194576b3812f9911ec7c96_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3d4326ed9749e08f9f55e523f5ee30_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb734ded22cc4f09a1e7aa403217a9eb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475da8e727be45c3b387f78b1fea2e7e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b6d20e6fbcf404989fa7f5435ba4ba6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic976412b06ed475dbb01665551f97bd7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2de02b1a13d4d139855d845acf40789_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e8976d4e1a4b71a27811336c8ab1f8_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7c26f3cd65d4c5d8f2b5bd56c02ed3d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f077fb9d5034effb52f4a2b5f9eef57_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33a26b2938054f1184c11ed6cf4b88f0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a88b4bdd8c94764a0107e43c486dc09_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d8278156114626afb74c2ac5266a22_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bd8ff0a20174e8aa35746d67cdc6c5a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cddddd8de4b47ea9ad8c08d1dbcfde7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea11b9899164f17b368e2e8e1fd6646_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c3371fdeb14d998c863d3e43e1fc97_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieafb2d92ce5b42eba36f9dd9ad33d3a5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf051fa36294b75bbdb2a6a108964d0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id73e900fdc57444dbbceb802f1d0608b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib07d526f34e8412e9d6ac51ac9f427f2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81eec297555347958006226c1ad5a577_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafbedc70de804139afe4d7945d4cb53d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcc31dc5500e46db949b0cb3ef157084_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a2ef424a8a8474cac5b9126f26ba070_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d05b9c8081748e2a9f6313aa40cc11b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if79c42dff8224bcd8bda45cfd70678a7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2555de19982c4c1c919234a3b7833ea2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e55884aa128493da77727ae7c6d1253_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23a8d86b9d8a4084b1e6ddcc45ead16a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a0c1c8ef9849838870a39529fcdb16_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5e0a45bdcbf45c7b2fdde90c75f5932_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50af60fd4c5f4255ac6d02be0a13ae03_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45a0926568d6467b9669368002f75388_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d037573a5d4222b17c5284accac4ec_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f866a6e7b4747ab9df0359131844149_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac1d092bd684cfe97e775dae9a43281_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b6d9f05d93342c9ac54a0fd0e292ec8_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ddc948c59f44ab9aeceef6ea85eea1b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c63832601e43b1ad4c8f083610e7c3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i850b26f85bd14a8598514f4059d09199_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id55db4e038a84957890427287eb9ab56_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92374c3d2722492fa34458de0e14064c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i599608cf1f684eed8b209bd530f295e9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i422216cc59db4c0c941301f559702000_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e19e67050949db82566d3868c92ad7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9afb09ccee54d4abc14d8bb45e5e1bb_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia20a5ce5890e4d60b4948961eba84c76_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00419766ad6e4ea89e37292413d0efab_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa1c27da4bbd4f5bb7644fd70f60b7ff_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6abe4cf6499f44b8864302dc6a141046_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib44237838e71484c841e5e53a3a8c7bb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4be2e62190a748c1a9f9858019ad5f2c_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7280243f94ec4714a8ecd07ad5de6b9b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bb69c6ba5614a0da3881621e639aaba_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95a799c54a94247a4f4738e17ef6bdd_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78fa9c5783f54e208617e980cb82b18c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c722ac2a4a64faa8604869f789d2250_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c379bb07b1f423494b9602d42fcbda1_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i599b25cf3d4a4566a4fb6560ac142a99_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa4a315b27d540e6a99eb9f14f0a2b22_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba96a050bfaa4084a8d2900a2e3a04d5_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74464a7622714b598ec7ac59bb92daa9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia431b44bdbc04745b1da9bc7e6129763_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c3fa299f6ba45c4b222ae1e49bcebb9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i386d38aa8c394c4f935a4311fd4ef278_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5940e0037084662b3d6936dc73b3ee8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a080af195245c883230bee9c30e225_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia55cc74e40ab4d0592d91514f04f2608_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91aa6b32077b4d2497b10c0c7a56e179_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a9e1c6f9634d72a1c5c2e943619a42_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97e2595ac4db46c4bddda29dbd79cb53_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icacd0f9bc97a476d9227cb9d73c43f17_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i555d0de63ee2467baa26c01abdb6a217_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0158c50e3f843b98737f71038b73b04_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad2240e53ec400db99843a0627fa101_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementB